QF
SMMT icon

QVT Financial’s Summit Therapeutics SMMT Stock Holding History

QVT Financial’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.25M Hold
360,524
– – 0.31% 33
2026
Q1 		$6.84M Hold
360,524
– – 0.5% 29
2025
Q4 		$6.31M Hold
360,524
– – 0.54% 24
2025
Q3 		$7.45M Hold
360,524
– – 0.53% 23
2025
Q2 		$7.67M Hold
360,524
– – 0.68% 26
2025
Q1 		$6.95M Hold
360,524
– – 0.64% 22
2024
Q4 		$6.43M Hold
360,524
– – 0.57% 20
2024
Q3 		$7.9M Sell
360,524
-215,181
-37% -$3.01M 0.68% 18
2024
Q2 		$4.49M Buy
+575,705
New +$3.11M 0.42% 20

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

QVT Financial's SMMT Position: Q2 2026 in Review

QVT Financial held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 360,524 shares worth $5.25M. The position accounts for 0.31% of the portfolio, ranked #33.

QVT Financial first reported a position in SMMT in Q2 2024 and has held it in 9 quarters since. The position peaked at $7.9M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • QVT Financial held 360,524 shares of Summit Therapeutics worth $5.25M as of Q2 2026.
  • QVT Financial left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up 0.31% of QVT Financial's portfolio in Q2 2026, its #33 holding.
  • QVT Financial first reported a position in Summit Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • QVT Financial's Summit Therapeutics position peaked at $7.9M in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on QVT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.